Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Raises Stake in Ibis Biosciences by $20M; Retains Right to Buy

NEW YORK (GenomeWeb News) – Abbott has invested a second $20 million in pathogen detection developer Ibis Biosciences, upping its stake in the company to 18.6 percent, Ibis parent firm Isis Pharmaceuticals said today.
The agreement follows a $20 million investment that Abbott made in January that gave it a 10.25 percent stake in the firm.
Ibis plans to use the cash to develop its T5000 Biosensor System, a system for rapidly identifying and characterizing infectious agents, including pandemic diseases, emerging or previously unknown pathogens, and hospital-acquired infections.
Abbott retains the exclusive option to purchase the remaining equity in Ibis for an additional $175 million to $190 million through June 30, 2009.
If Abbott purchases Ibis, it will owe Isis earn-out money related to certain sales.
"We are aggressively accelerating the expansion of our commercial products into larger market opportunities, and this recent financing from Abbott will provide the capital to continue on this path," said Ibis president Michael Treble in a statement.
The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.